Literature DB >> 24241790

Glucagon response to oral glucose challenge in type 1 diabetes: lack of impact of euglycemia.

Caroline K Kramer1, Carla A Borgoño, Paula Van Nostrand, Ravi Retnakaran, Bernard Zinman.   

Abstract

OBJECTIVE Previous studies have demonstrated aberrant glucagon physiology in the setting of type 1 diabetes (T1D) but have not addressed the potential impact of ambient glycemia on this glucagon response. Thus, our objective was to evaluate the impact of euglycemia versus hyperglycemia on the glucagon response to an oral glucose challenge in T1D. RESEARCH DESIGN AND METHODS Ten adults with T1D (mean age 56.6 ± 9.0 years, duration of diabetes 26.4 ± 7.5 years, HbA1c 7.5% ± 0.77, and BMI 24.1 kg/m(2) [22.6-25.4]) underwent 3-h 50-g oral glucose tolerance tests (OGTTs) on two separate days at least 24 h apart in random order under conditions of pretest euglycemia (plasma glucose [PG] between 4 and 6 mmol/L) and hyperglycemia (PG between 9 and 11 mmol/L), respectively. RESULTS Glycemic excursion on the OGTT was similar between the euglycemic and hyperglycemic tests (P = 0.72 for interaction between time postchallenge and glycemic setting). Interestingly, glucagon levels increased in response to the OGTT under both glycemic conditions (P < 0.001) and there were no differences in glucagon response between the euglycemic and hyperglycemic days (P = 0.40 for interaction between time postchallenge and glycemic setting). In addition, the incretin responses to the OGTT (glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, glucagon-like peptide-2) were also not different between the euglycemic and hyperglycemic settings. CONCLUSIONS In patients with T1D, there is a paradoxical increase in glucagon in response to oral glucose that is not reversed when euglycemia is achieved prior to the test. This abnormal glucagon response likely contributes to the postprandial hyperglycemia in T1D irrespective of ambient glycemia.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24241790     DOI: 10.2337/dc13-2339

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  11 in total

1.  Early Alterations in Glycemic Control and Pancreatic Endocrine Function in Nondiabetic Patients With Chronic Pancreatitis.

Authors:  Rachel Lundberg; Gregory J Beilman; Ty B Dunn; Tim L Pruett; Martin L Freeman; Peggy E Ptacek; Katherine Louise Berry; R Paul Robertson; Antoinette Moran; Melena D Bellin
Journal:  Pancreas       Date:  2016-04       Impact factor: 3.327

2.  Multicenter closed-loop/hybrid meal bolus insulin delivery with type 1 diabetes.

Authors:  H Peter Chase; Francis J Doyle; Howard Zisser; Eric Renard; Revital Nimri; Claudio Cobelli; Bruce A Buckingham; David M Maahs; Stacey Anderson; Lalo Magni; John Lum; Peter Calhoun; Craig Kollman; Roy W Beck
Journal:  Diabetes Technol Ther       Date:  2014-09-04       Impact factor: 6.118

Review 3.  Islet α cells and glucagon--critical regulators of energy homeostasis.

Authors:  Jonathan E Campbell; Daniel J Drucker
Journal:  Nat Rev Endocrinol       Date:  2015-04-07       Impact factor: 43.330

4.  The effects of add-on exenatide to insulin on glycemic variability and hypoglycemia in patients with type 1 diabetes mellitus.

Authors:  L-L Jiang; S-Q Wang; B Ding; J Zhu; T Jing; L Ye; K-O Lee; J-D Wu; J-H Ma
Journal:  J Endocrinol Invest       Date:  2017-10-14       Impact factor: 4.256

5.  Inappropriate glucagon and GLP-1 secretion in individuals with long-standing type 1 diabetes: effects of residual C-peptide.

Authors:  Charles Thivolet; Lucien Marchand; Karim Chikh
Journal:  Diabetologia       Date:  2019-01-06       Impact factor: 10.122

6.  The influence of glucagon on postprandial hyperglycaemia in children 5 years after onset of type 1 diabetes.

Authors:  Siri Fredheim; Marie-Louise M Andersen; Sven Pörksen; Lotte B Nielsen; Christian Pipper; Lars Hansen; Jens J Holst; Jane Thomsen; Jesper Johannesen; Henrik B Mortensen; Jannet Svensson
Journal:  Diabetologia       Date:  2014-12-27       Impact factor: 10.122

7.  Decreased α-cell mass and early structural alterations of the exocrine pancreas in patients with type 1 diabetes: An analysis based on the nPOD repository.

Authors:  Fidéline Bonnet-Serrano; Marc Diedisheim; Roberto Mallone; Etienne Larger
Journal:  PLoS One       Date:  2018-01-19       Impact factor: 3.240

8.  Protocol for Meal-time Administration of Exenatide for Glycaemic Control in Type 1 Diabetes Cases (The MAG1C trial): a randomised, double-blinded, placebo-controlled trial.

Authors:  Nicklas Järvelä Johansen; Thomas Fremming Dejgaard; Asger Lund; Tina Vilsbøll; Henrik Ullits Andersen; Filip Krag Knop
Journal:  BMJ Open       Date:  2018-06-27       Impact factor: 2.692

Review 9.  Cell Heterogeneity and Paracrine Interactions in Human Islet Function: A Perspective Focused in β-Cell Regeneration Strategies.

Authors:  Eva Bru-Tari; Daniel Oropeza; Pedro L Herrera
Journal:  Front Endocrinol (Lausanne)       Date:  2021-02-03       Impact factor: 5.555

10.  Impact of glucagon response on early postprandial glucose excursions irrespective of residual β-cell function in type 1 diabetes: A cross-sectional study using a mixed meal tolerance test.

Authors:  Ayako Ito; Ichiro Horie; Masaki Miwa; Ayaka Sako; Tetsuro Niri; Yomi Nakashima; Riyoko Shigeno; Ai Haraguchi; Shoko Natsuda; Satoru Akazawa; Akie Kamada; Atsushi Kawakami; Norio Abiru
Journal:  J Diabetes Investig       Date:  2021-01-22       Impact factor: 4.232

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.